Trial Profile
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Cisplatin; Ipilimumab; Nivolumab; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms DREAM3R
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.